Phospho-CASP9 (S196) Antibody

What is Phospho-CASP9 (S196) Antibody?

Phospho-CASP9 (S196) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of Caspase-9 protein only when phosphorylated at the Serine 196 residue. This antibody typically recognizes the phosphorylated epitope derived from human Caspase-9 around the S196 phosphorylation site. It's available as an unconjugated antibody and is commonly used in several experimental applications including Western blot (WB), immunohistochemistry (IHC), and ELISA .

The antibody specifically binds to the phosphorylated form of Caspase-9, which is crucial for studying regulatory mechanisms of apoptosis. Most formulations are supplied in PBS containing a preservative like sodium azide and stabilizers such as glycerol and BSA .

What is the structural and functional significance of Caspase-9?

Caspase-9 (also known as APAF-3, ICE-LAP6, or MCH6) is a critical initiator caspase in the intrinsic apoptotic pathway. Structurally, it contains:

• An N-terminal CARD (Caspase Recruitment Domain) for interaction with Apaf-1

• A large subunit (p35) and a small subunit (p10) that form the catalytic domain

• Multiple regulatory phosphorylation sites that modulate its activity

Functionally, Caspase-9 plays a central role in apoptosis execution. When cytochrome c is released from mitochondria, it binds to Apaf-1, leading to the formation of the apoptosome complex. This complex recruits and activates procaspase-9 through CARD-CARD interactions. Activated Caspase-9 then cleaves and activates downstream executioner caspases like Caspase-3, initiating the apoptotic cascade .

How does phosphorylation at S196 regulate Caspase-9 function?

Phosphorylation at Serine 196 functions primarily as an inhibitory mechanism that suppresses Caspase-9 activation. When Caspase-9 is phosphorylated at S196, its ability to initiate apoptosis is significantly reduced. This phosphorylation appears to be part of a survival mechanism in cells.

Studies have shown that phosphorylation at S196 inhibits Caspase-9 activation in epithelial cells expressing mutant Ras. Initial research suggested this phosphorylation was mediated by Akt, though subsequent studies have questioned this direct relationship .

The regulatory significance of this phosphorylation is highlighted in growth factor signaling pathways. For example, treatment with platelet-derived growth factor (PDGF) enhances Caspase-9 phosphorylation at S196, which correlates with increased levels of pro-Caspase-9 and pro-Caspase-3, suggesting a protective mechanism against apoptosis .

What are the validated applications for Phospho-CASP9 (S196) Antibody?

The Phospho-CASP9 (S196) Antibody has been validated for several experimental applications:

Each application requires specific optimization for the particular experimental system being used. The antibody has demonstrated reactivity with human Caspase-9 phosphorylated at S196, making it suitable for studies investigating regulatory mechanisms of apoptosis in human cells and tissues .

What controls should be included when using Phospho-CASP9 (S196) Antibody?

When using Phospho-CASP9 (S196) Antibody, several controls should be incorporated to ensure experimental validity:

• Positive control: Lysates from cells treated with agents known to induce S196 phosphorylation (e.g., PDGF-treated human airway smooth muscle cells)

• Negative control:

  • Samples treated with phosphatase to remove phosphorylation

  • Samples from cells where relevant kinase pathways are inhibited

• Specificity control:

  • Competing peptide blocking experiments using the phosphorylated immunogen peptide

  • Use of S196A mutant Caspase-9 expressing cells

• Loading control: Detection of total Caspase-9 or housekeeping proteins in parallel

• Cross-reactivity assessment: Testing the antibody against murine Caspase-9 (note: S196 is not conserved in rodents)

These controls help validate antibody specificity and ensure that observed signals are genuinely representing phosphorylated Caspase-9 at S196.

What kinases phosphorylate Caspase-9 at S196?

The phosphorylation of Caspase-9 at S196 involves several kinases, though some aspects remain controversial:

It's worth noting that the kinase(s) responsible may vary depending on cell type and physiological context, highlighting the complexity of Caspase-9 regulation in different cellular environments.

How does PDGF signaling influence Caspase-9 phosphorylation at S196?

PDGF signaling plays a significant role in regulating Caspase-9 phosphorylation at S196:

• Time-dependent response: Treatment with PDGF-BB (10 ng/ml) enhances Caspase-9 phosphorylation at S196 in a time-dependent manner. This effect begins approximately 6 hours after treatment, peaks at 24 hours, and starts to decrease by 48 hours .

• Receptor dependency: The PDGF receptor inhibitor AG1296 significantly reduces Caspase-9 phosphorylation at S196, confirming that this effect is dependent on PDGF receptor activation .

• Selective phosphorylation pattern: Interestingly, PDGF promotes phosphorylation of Caspase-9 at S196 but not at another regulatory site, Thr-125. This suggests a selective activation of specific regulatory pathways .

• Plk1 involvement: PDGF treatment increases both Plk1 expression and Caspase-9 S196 phosphorylation, suggesting that Plk1 may be an intermediary in this signaling pathway .

The PDGF-induced phosphorylation of Caspase-9 at S196 may represent a survival mechanism, protecting cells from apoptosis by inhibiting Caspase-9 activation in response to growth factor stimulation.

What are the optimal conditions for using Phospho-CASP9 (S196) Antibody in Western blot?

To achieve optimal results with Phospho-CASP9 (S196) Antibody in Western blot experiments:

• Sample preparation:

  • Lyse cells in a phosphatase inhibitor-containing buffer to preserve phosphorylation status

  • Use fresh samples or properly stored frozen samples (-80°C)

  • Avoid repeated freeze-thaw cycles that can degrade phospho-epitopes

• Protein loading and transfer:

  • Load 20-40 μg of total protein per lane

  • Use PVDF membrane for better protein retention and signal

  • Ensure complete transfer using a prestained marker

• Blocking and antibody incubation:

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

  • Use antibody at recommended dilution (1:500-1:2000)

  • Incubate overnight at 4°C for primary antibody

• Detection and visualization:

  • Use high-sensitivity ECL substrate for optimal detection

  • Expected molecular weight: ~50kDa (observed), 46kDa (calculated)

  • Strip and reprobe with total Caspase-9 antibody for normalization

Following these guidelines will help ensure specific and sensitive detection of Caspase-9 phosphorylated at S196 in your experimental system.

How can I troubleshoot weak or absent signals when using Phospho-CASP9 (S196) Antibody?

When encountering weak or absent signals with Phospho-CASP9 (S196) Antibody, consider these troubleshooting steps:

• Phosphorylation status issues:

  • Confirm your treatment actually induces S196 phosphorylation (e.g., PDGF treatment for 24 hours has been shown to be effective)

  • Ensure phosphatase inhibitors are fresh and used at appropriate concentrations

  • Minimize sample handling time to prevent dephosphorylation

• Antibody-related issues:

  • Verify antibody hasn't expired or degraded (store at -20°C or -80°C and avoid repeated freeze-thaw cycles)

  • Try increasing antibody concentration or incubation time

  • Consider using a different lot or source of the antibody

• Technical considerations:

  • Optimize protein extraction method for your specific cell/tissue type

  • Increase protein loading (up to 60-80 μg per lane)

  • Extend exposure time during detection

  • Try more sensitive detection methods (e.g., enhanced chemiluminescence plus)

• Experimental validation:

  • Include a positive control (PDGF-treated cells)

  • Test the antibody on cells with known high levels of S196 phosphorylation

  • Consider using phosphatase treatment as a negative control

If signal remains problematic after these steps, it may be necessary to reassess if S196 phosphorylation occurs in your experimental system or if alternative antibodies should be tested.

How does phosphorylation at S196 compare to other Caspase-9 phosphorylation sites?

Caspase-9 is regulated by phosphorylation at multiple sites, each with distinct functional implications:

Notably, while PDGF promotes phosphorylation at Ser196, it does not affect Thr125 phosphorylation, suggesting distinct regulatory pathways for different phosphorylation sites .

The lack of conservation of the S196 site between humans and rodents presents an important consideration for translational research, as murine models may not fully recapitulate human Caspase-9 regulation at this specific site .

How can I design experiments to investigate the temporal dynamics of Caspase-9 S196 phosphorylation?

To effectively study the temporal dynamics of Caspase-9 S196 phosphorylation:

• Time-course experiments:

  • Treat cells with relevant stimuli (e.g., PDGF-BB at 10 ng/ml) for varying durations (5 min to 48 hours)

  • Research shows PDGF-induced phosphorylation begins at 6 hours, peaks at 24 hours, and decreases by 48 hours

  • Collect samples at regular intervals to capture the complete phosphorylation profile

• Pulse-chase approaches:

  • Apply stimulus, then remove or inhibit it to study dephosphorylation kinetics

  • Use selective inhibitors at different time points to determine critical windows

• Real-time monitoring:

  • Develop FRET-based biosensors for Caspase-9 S196 phosphorylation

  • Use live-cell imaging to visualize phosphorylation dynamics in real-time

• Synchronized cell populations:

  • Study S196 phosphorylation across different cell cycle phases

  • Determine if phosphorylation status changes during specific cellular events

• Multi-parameter analysis:

  • Simultaneously monitor Caspase-9 S196 phosphorylation, total Caspase-9 levels, and relevant kinase activities (e.g., Plk1)

  • Correlate phosphorylation status with functional outcomes like apoptosis resistance

This experimental approach can reveal both the kinetics of phosphorylation and the relationship between S196 phosphorylation and cellular outcomes in various physiological and pathological contexts.

What approaches can be used to investigate the functional significance of Caspase-9 S196 phosphorylation?

To elucidate the functional significance of Caspase-9 S196 phosphorylation:

• Phospho-mutant studies:

  • Generate S196A (phospho-deficient) and S196D/E (phospho-mimetic) Caspase-9 mutants

  • Express in Caspase-9 knockout or knockdown cells

  • Compare apoptotic responses to various stimuli

  • Previous research has shown that S196A mutant procaspase-9 induces Akt-resistant apoptosis

• Kinase manipulation:

  • Modulate activities of kinases implicated in S196 phosphorylation (Plk1, Akt)

  • Use pharmacological inhibitors, genetic knockdown, or overexpression approaches

  • Assess impact on Caspase-9 phosphorylation and cellular apoptotic responses

• Context-dependent studies:

  • Compare S196 phosphorylation status in:

    • Normal versus cancer cells

    • Different tissue types

    • Various stress conditions (hypoxia, DNA damage, etc.)

• Structural and biochemical analyses:

  • Use molecular dynamics simulations to understand how S196 phosphorylation affects Caspase-9 structure

  • Perform in vitro reconstitution assays to determine impact on apoptosome formation and caspase activation

• Correlation with clinical outcomes:

  • Assess S196 phosphorylation status in patient samples

  • Correlate with disease progression, treatment response, or survival rates

These approaches collectively provide a comprehensive understanding of how S196 phosphorylation regulates Caspase-9 function in different biological contexts.

What is the relationship between Plk1 and Caspase-9 phosphorylation at S196?

The relationship between Polo-like kinase 1 (Plk1) and Caspase-9 phosphorylation at S196 represents an important regulatory mechanism:

• Expression correlation:

  • PDGF treatment increases both Plk1 expression and Caspase-9 S196 phosphorylation with similar temporal dynamics

  • Both begin to increase at 6 hours post-treatment, peak at 24 hours, and decrease by 48 hours

• Pathway dependency:

  • PDGF receptor inhibition with AG1296 reduces both Plk1 expression and Caspase-9 S196 phosphorylation

  • This suggests a pathway where PDGF receptor activation leads to increased Plk1 expression, which in turn may mediate Caspase-9 S196 phosphorylation

• Functional implications:

  • Plk1-mediated phosphorylation of Caspase-9 at S196 may represent a survival mechanism by inhibiting apoptosis

  • This could be particularly relevant in contexts where Plk1 is overexpressed, such as in certain cancers

• Therapeutic significance:

  • Targeting the Plk1-Caspase-9 axis could potentially enhance apoptotic responses in treatment-resistant cells

  • Plk1 inhibitors might increase cancer cell sensitivity to apoptosis by reducing Caspase-9 S196 phosphorylation

Further research is needed to fully elucidate whether Plk1 directly phosphorylates Caspase-9 at S196 or acts through intermediate signaling molecules, as well as the mechanisms by which Plk1 expression is regulated in response to PDGF.